E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bladder dysfunction in Multiple Sclerosis |
Blaas dysfunctie bij Multipele Sclerose |
|
E.1.1.1 | Medical condition in easily understood language |
Bladder dysfunction in MS |
Blaasledigingsstoornis bij MS |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10069632 |
E.1.2 | Term | Bladder dysfunction |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Improves the alpha blocker Silodosin the bladder emptying in patients with MS? |
Verbetert de alpha-blokker silodosine de blaaslediging bij patiënten met MS? |
|
E.2.2 | Secondary objectives of the trial |
Improves the alpha blocker Silodosin the quality of life of patients with MS? |
Verbetert de alpha-blokker silodosine de kwaliteit van leven van patiënten met MS? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Female
- Age ≥ 18 years
- Any form of MS
- Residual urine 60 ml - 250 ml
- Adequate understanding of the Dutch language |
- Vrouw
- Leeftijd ≥ 18 jaar
- Alle vormen van MS
- Urineresidu 60 ml - 250 ml
- Adequaat begrip van de Nederlandse taal |
|
E.4 | Principal exclusion criteria |
- Dependency of wheel chair
- Being bedridden
- Indwelling catheter
- Clean intermittent catheterization
- Acute attack of MS
- Current treatment with an alpha-blocker
- Pregnancy/breastfeeding
- Severe kidney dysfunction
- Orthostatic hypotension
|
- Rolstoelafhankelijkheid
- Bedlegerigheid
- Verblijfscatheter
- Intermitterende catheterisatie
- Acute MS aanval
- Huidige behandeling met een alpha-blocker
- Zwangerschap / geeft borstvoeding
- Ernstige nierdysfunctie
- Orthostatische hypotensie |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Residual urine, measured within 10 minutes after a voluntary void at t=0 and t=6 weeks. |
Urineresidu, gemeten binnen 10 minuten na het legen van de blaas op t=0 en t=6 weken. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
t=0 and t=6 weeks. |
t=0 en t=6 weken. |
|
E.5.2 | Secondary end point(s) |
- Quality of life (questionnaire: Qualiveen) at t=0 and t=6 weeks.
- Symptom scores of voiding complaints (questionnaires: UDI-6 and IIQ-7) at t=0 and t=6 weeks. |
- Kwaliteit van leven (Qualiveen vragenlijst) op t=0 en t=6 weken.
- Symptoom scores van plasklachten (UDI-6 and IIQ-7) op t=0 en t=6 weken. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
t=0 and t=6 weeks. |
t=0 en t=6 weken. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit. |
Laatste visite van de laatste patiënt. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |